



NCG-KCDO EMR Requirement (NER)-Pain Management Module (Version 1.0)





FOREWORD

The National Cancer Grid (NCG) Electronic Medical Records (EMR) initiative has been well received by the NCG Hospitals and our community of healthcare professionals and stakeholders. The enthusiasm and support we have garnered for this initiative reflect a shared commitment to advancing cancer care through technology and collaboration.

As part of our ongoing efforts to enhance the EMR initiative, the pain management module has been developed. This module aims to streamline the process, providing clinicians with the tools they need to deliver optimal care to patients with cancer.

We share the pre-final version of the module and welcome feedback, suggestions and guidance from the healthcare professionals involved in treating patients with cancer, healthcare technology companies and providers. Your inputs will help develop EMRs with strong cancer care workflows which in turn will ensure better care, outcomes and value-based care for patients with cancer across India.

Dr C.S. Pramesh Convener, National Cancer Grid August 2024





Contents

1. NCG EMR INITIATIVE OVERVIEW	4
2. EMR FEATURE BUILDING	4
A. Pain Management Module Overview	4
B. Methodology	5
3. PM- Part A: Pain Management Form- New	5
4. PM- Part B: Pain Management Form- Follow Up	10
5. PM- Part C: Pain Management Form- Nerve Block	14
6. Appendices	17
Appendix 1- Glossary of terms	17
Appendix 2- NER Document	17





1. NCG EMR INITIATIVE OVERVIEW

The National Cancer Grid Koita Centre for Digital Oncology (NCG KCDO) launched an initiative to empanel Electronic Medical Records (EMR) vendors and help develop high quality EMR solutions that are appropriate for use in hospitals providing cancer care. This marks a significant milestone in the ongoing efforts to promote digital health and enhance cancer care across the country. Launched with the aim of standardizing and improving clinical practices in oncology, it is a collaborative approach involving leading healthcare institutions, clinicians, and technology partners.

In March 2023, NCG KCDO released the NCG EMR Requirements (NER) – a comprehensive set of EMR requirements needed for effective management of patients with cancer. The NER is a blueprint for the development and implementation of robust EMR systems which will serve general hospitals well, but are also tailored specifically for oncology practices. The NER document is a result of intense deliberations over several months between healthcare professionals involved in cancer care and technology experts, and is available as a digital public good at NCG-KCDO EMR Initiative.

To further support the development of the empanelled EMR systems, the NCG has developed detailed requirements and features in specific areas of oncology including radiotherapy, chemotherapy and surgical oncology. This document details the pain management requirements based on best practices developed at several leading NCG centres.

2. EMR FEATURE BUILDING

A. Pain Management Module Overview

Building on the features outlined in the NER (NCG EMR Requirement), the Pain Management Module is designed to streamline and optimize the treatment process for patients with cancer. The module is designed to enhance the quality, safety, and efficiency of the treatment within the NCG network, ultimately improving outcomes for cancer patients and advancing the field of oncology care.

Key features of the Pain Management module include:

- **2.1 Pain Characteristics:** Documents the site, type, intensity, and duration of pain.
- **2.2 Quality of Life:** Assesses the impact of pain on sleep, mood, and daily activities.
- **2.3 Current Medication and Treatment Plan:** Lists medications being taken and plans for ongoing pain management.
- **2.4 Procedure Details:** Documents the type of nerve block, drugs used, and imaging guidance.
- **2.5 Pre- and Post-Procedure Assessment:** Includes vital signs and pain scores before and after the procedure.





B. Methodology

The methodology used to build the pain management module within the NER (NCG EMR Requirements) document encompasses a systematic and collaborative approach, involving key stakeholders and leveraging best practices across NCG hospitals.

The pain management form is characterized into 3 parts:

PM- Part A: Pain Management Form-New - This section collects essential patient data including general details, diagnosis, pain score, treatment history, and consent.

PM- Part B: Pain Management Form-Follow Up - The section records previous assessment details and current treatment, including the type and location of pain, pain score, and any aggravating factors. Auto-populate fields from previous assessments to ensure continuity of care and enable accurate tracking of changes.

PM- Part C: Pain Management Form-Nerve Block - The section documents procedure details such as the type of nerve block performed, drugs used, and imaging guidance. Pre- and post-procedure assessments include vital signs and pain scores to monitor patient response and immediate complications.

3. PM- Part A: Pain Management Form- New

		New Pain Management Form	1
Sno	Data elements	Clinician's Response	Remarks for Vendors
1	General Details		
Α	Case Number		
В	Name		Auto populate as per case no
С	Age		Auto populate as per case no
D	Sex		Auto populate as per case no
Е	Diagnosis		Auto populate as per case no
F	Phone Number		Auto populate as per case no
G	Service	□ OPD □ Ward	
Н	Name of the Pain Physician		Add the doctors as per the facility
l	Surgery		Auto populate from EMR





J	Chemotherapy				Auto pop	ulate from EMR
K	Radiotherapy				Auto pop	ulate from EMR
L	Pre- Existing Chror disease	nic	☐ COPD ☐ Epilepsy ☐ Asthma ☐ HT ☐ DM ☐ IHD ☐ Others, Pls S ☐ None	pecify	Multiple	Choice Possible
2	Investigations					
Α	CBC				Link to Ef	MR
В	RFT				Link to Ef	MR
С	LFT				Link to Ef	MR
D	Any other, Specify				Link to Ef	MR
3	Pain Characteristic	cs				
Α	Site				Open tex	t box
В	Radiates to				Open tex	t box
С	Type of Pain				Choose f	rom the table below
Mult possi	iple choice ble	Single cl	noice possible	Single choice	oossible	Single choice possible
□Bu	ırning	☐ Local	ised	☐ Continuous		☐ Breakthrough
	abbing	☐ Gene	ralised	☐ Intermitten	t	□ Incidental
	ıll Aching					☐ Spontaneous
	umbness 					
	icking					
	ooting asmodic					
-	ngling					
D	Pain score				Please pr	ovide options from 0-10
Е	Duration					eks/Months
F	No of episodes of	ВТР			Please pr	ovide options from 0-9
			☐ After meals			
G	Aggravating Factor	rs	☐ On moveme	nt	Multiple	choice Possible
			☐ Not related			





		☐ On Swallowing	
		☐ Coughing	
		☐ Others	
Н	Pain Pathophysiology	☐ Somatic☐ Visceral☐ Neuropathic☐ Psychogenic	Multiple choice Possible
ı	Pain Syndrome	☐ Head and Neck Cancer Pain Syndrome ☐ Post Mastectomy Pain ☐ Visceral Pain Syndrome ☐ Pelvic Pain Syndrome ☐ Skeletal Metastatis ☐ STS Pain Syndrome ☐ Bracheal Plexopathy ☐ Lumbosacral Plexopathy ☐ Post Thoracotomy Pain ☐ Post CT Pain ☐ Phantom Limb Pain ☐ CRPS	Multiple choice Possible
J	Pain diagnosis	☐ Due to cancer☐ Cancer Therapy☐ Unrelated	
К	Click to add/View Pain Image		
4	Quality of Life		
Α	Affected	☐ Sleep ☐ Mood ☐ Bladder ☐ Bowel ☐ Others ☐ None	Multiple choice Possible
В	Karnofsky Performance Scale	□ >80% Normal activity with no special care □ 50-70% Unable to work but able to live at home □ <50% Needs Hospital Care	
С	Diagnosis Made By	□ X-Ray □ CT	Auto Populate the reports as per the option selected. Multiple Choice Possible





			☐ Bone Scan ☐ Clinical ☐ USG ☐ MRI ☐ PET			
5	Current Medicatio	on	☐ Morphine ☐ Tapentadol ☐ Paracetamo ☐ Transderma ☐ Codeine ☐ Transderma Buprenorphine ☐ Tramadol ☐ Diclofenac ☐ Ibuprufen ☐ Others ☐ None	l Fentanyl I	Multiple	choice Possible
C	Treatment Plan					
6	Treatment Plan					
Α	Opioid				Multiple	Choice possible
Drug	, Name	Dosage		Unit		Frequency
☐ Bu	prenorphine TD	Dosage		Unit mcg		☐ 4 Hourly
☐ Bu	uprenorphine TD n	Dosage		mcg		☐ 4 Hourly ☐ 6 Hourly
□ Bu Patch	uprenorphine TD n odeine	Dosage		mcg mg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly
□ Bu Patch	uprenorphine TD n	Dosage		mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly
☐ Bu Patch ☐ Co	uprenorphine TD n odeine uprenorphine	Dosage		mcg mg mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD
☐ Bu Patch ☐ Co ☐ Bu	uprenorphine TD n odeine uprenorphine orphine	Dosage		mcg mg mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days
☐ Bu Patch ☐ Co ☐ Bu ☐ M ☐ Fe	uprenorphine TD n odeine uprenorphine	Dosage		mcg mg mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days
☐ Bu Patch ☐ Co ☐ Bu ☐ M ☐ Fe Trans	uprenorphine TD odeine uprenorphine orphine	Dosage		mcg mg mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ SOS
☐ Bu Patch ☐ Co ☐ Bu ☐ M ☐ Fe Trans ☐ Ta	uprenorphine TD odeine uprenorphine orphine entanyl sdermal Patch	Dosage		mcg mg mcg mg mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days
☐ Bu Patch ☐ Co ☐ Bu ☐ M ☐ Fe Trans ☐ Ta	uprenorphine TD odeine uprenorphine orphine entanyl sdermal Patch pentadol	Dosage		mcg mg mcg mg mg mrg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ SOS
☐ Bu Patch ☐ Co ☐ Bu ☐ M ☐ Fe Trans ☐ Ta ☐ M ☐ Tra	uprenorphine TD n odeine uprenorphine orphine entanyl sdermal Patch pentadol ethadone	Dosage		mcg mg mcg mg mcg mg mcg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ SOS
Bu Patch Co Bu M Fe Trans M Ta BT	uprenorphine TD odeine uprenorphine orphine entanyl sdermal Patch pentadol ethadone amadol	Dosage		mcg mg mcg mg mcg mg mcg mg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ SOS
Bu Patch Co Bu M Fe Trans M Ta BT	uprenorphine TD n odeine uprenorphine orphine entanyl sdermal Patch pentadol ethadone amadol TP dose of	Dosage		mcg mg mcg mg mcg mg mcg mg		☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ SOS
Bu Patch Co Bu M Fe Trans M Trans BT	uprenorphine TD n odeine uprenorphine orphine entanyl sdermal Patch pentadol ethadone amadol TP dose of	Dosage		mcg mg mcg mg mcg mg mcg mg	Multiple	☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ SOS
☐ Bu Patch ☐ Co ☐ Bu ☐ M ☐ Fe Trans ☐ Ta ☐ M ☐ Tra ☐ M ☐ BT Morp	uprenorphine TD n odeine uprenorphine orphine entanyl sdermal Patch pentadol ethadone amadol TP dose of ohine	Dosage		mcg mg mcg mg mcg mg mcg mg	Multiple	☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ HS
□ Bu Patch □ Co □ Bu □ M □ Fe Trans □ Ta □ M □ Tra □ BT Morp	uprenorphine TD n odeine uprenorphine orphine entanyl sdermal Patch pentadol ethadone amadol TP dose of ohine	Dosage		mcg mg mcg mg mcg mg mcg mg	Multiple	☐ 4 Hourly ☐ 6 Hourly ☐ 8 Hourly ☐ 12 Hourly ☐ OD ☐ 3 days ☐ 7 days ☐ HS





□ Et	oricoxib			mg	☐ 6 Hourly
□ Ib	uprofen			mg	☐ 8 Hourly
	ceclofenac			mg	☐ 12 Hourly
					□OD
					☐ 3 days
					☐ 7 days
					□sos
					□ HS
		<u> </u>			
С	Paracetamol				
	Name	Dosage		Unit	Frequency
☐ Pa	racetamol			mg	☐ 4 Hourly
					☐ 6 Hourly
					☐ 8 Hourly
					☐ 12 Hourly
					□ OD
					☐ 3 days
					☐ 7 days
					□ sos
					□ HS
					L 113
D	Adjuvants				
	Adjuvants Name	Dosage		Unit	Frequency
Drug □ Ga	; Name abapentin	Dosage		Unit mg	
Drug □ Ga	Name	Dosage			Frequency
Drug ☐ Ga	; Name abapentin	Dosage		mg	Frequency □ 4 Hourly
Drug ☐ Ga ☐ Pr ☐ Ar	s Name abapentin regabalin	Dosage		mg mg	Frequency □ 4 Hourly □ 6 Hourly
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage		mg mg mg	Frequency 4 Hourly 6 Hourly 8 Hourly
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage		mg mg mg	Frequency
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage		mg mg mg	Frequency
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage		mg mg mg	Frequency
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage		mg mg mg	Frequency 4 Hourly 6 Hourly 8 Hourly 12 Hourly OD 3 days
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage		mg mg mg	Frequency 4 Hourly 6 Hourly 12 Hourly 0D 3 days 7 days SOS
Drug ☐ Ga ☐ Pr ☐ Ar	s Name abapentin regabalin mitryptiline ortryptiline	Dosage	□Yes	mg mg mg	Frequency 4 Hourly 6 Hourly 12 Hourly 0D 3 days 7 days SOS
Drug ☐ Ga ☐ Pr ☐ Ar	g Name abapentin regabalin mitryptiline	Dosage	□ No	mg mg mg	Frequency 4 Hourly 6 Hourly 12 Hourly 0D 3 days 7 days SOS
Drug Ga Pr Ar No	s Name abapentin regabalin mitryptiline ortryptiline Laxatives	Dosage	□ No □ Yes	mg mg mg	Frequency 4 Hourly 6 Hourly 12 Hourly 0D 3 days 7 days SOS
Drug ☐ Ga ☐ Pr ☐ Ar	s Name abapentin regabalin mitryptiline ortryptiline	Dosage	□ No	mg mg mg	Frequency 4 Hourly 6 Hourly 12 Hourly 0D 3 days 7 days SOS
Drug Ga Pr Ar	s Name abapentin regabalin mitryptiline ortryptiline Laxatives	Dosage	□ No □ Yes	mg mg mg	Frequency 4 Hourly 6 Hourly 12 Hourly 0D 3 days 7 days SOS





Н	Cyclopam (Dicyclomine)	☐ Yes ☐ No	
1	Bisphosphonates	☐ Yes	
•	Bispirespireriates	□ No	
		☐ Yes	
J	Baclofen		
		□ No	
K	Antiomotic	☐ Yes	
K	Antiemetic	□ No	
-		☐ Yes	
L	Antacid		
		□ No	
М	Elupiriting	☐ Yes	
IVI	Flupiritine	□ No	
N	Advice		Open text Box
			·

4. PM- Part B: Pain Management Form- Follow Up

Pain Management Form- Follow up				
Sno	Data elements	Clinician's Response	Remarks for Vendors	
1	General Details			
Α	Case Number			
В	Name		Auto populate as per case no	
С	Age		Auto populate as per case no	
D	Sex		Auto populate as per case no	
E	Diagnosis		Auto populate as per case no	
F	Phone Number		Auto populate as per case no	
G	Service	□ OPD		
		☐ Ward		
Н	Name of the Pain		Add the doctors as per the facility	
	Physician			
1	Surgery		Auto populate from EMR	
J	Chemotherapy		Auto populate from EMR	





K	Radiotherapy		Auto populate from EMR
L	Pre- Existing Chronic disease	☐ COPD ☐ Epilepsy ☐ Asthma ☐ HT ☐ DM ☐ IHD ☐ Others ☐ None	Multiple Choice Possible
2	Previous assessment detail	c	
	1 Tevious assessment detail	3	
Α	Site		Auto populate from new form
В	Radiates To		Auto populate from new form
С	Type of Pain		Auto populate from new form
D	Pain Score		Auto populate from new form
Е	Duration		Auto populate from new form
F	Aggravating Factors		Auto populate from new form
G	Name of Nerve Block		Auto populate from new form
Н	Date of Procedure		Auto populate from new form
ı	Present Treatment		Auto populate from new form
J	Laxatives		Auto populate from new form
K	Hyoscine		Auto populate from new form
L	Steroids		Auto populate from new form
М	Cyclopam (Dicyclomine)		Auto populate from new form
N	Bisphosphonates		Auto populate from new form
0	Baclofen		Auto populate from new form
Р	Antiemetic		Auto populate from new form
Q	Antacid		Auto populate from new form
R	Flupiritine		Auto populate from new form
3	Change treatment		
Α	Do you want to change treatment?	☐ Yes ☐ No	
В	Pain Score		Please provide options from 0-10
С	Overall Pain Relief	□ <30% □ 40% □ 50% □ 60% □ 70% □ >80%	·





-							
	D	Drug Compliance		□ Good			
				☐ Fair ☐ Poor			
	E	Karnofsky Perform	ance	□ >80%			
	_	Scale		□ 50-70%			
				□ <50%			
	F	No of episodes of	ВТР			Please pr	ovide options from 0-9
	4	Investigations					
	Α	CBC				Link to El	
_	В	RFT				Link to El	
	С	LFT				Link to El	MR
_	5	New Pain					
	3	New Falli					
_	Α	New Pain		□ Yes		If ves En	able Rows from 5B till 50
	^	New Fair		□ res		11 yes, E11	able nows from 35 till 30
	В	Site				Open tex	t box
	С	Radiates to				Free text	box
	D	Type of Pain				Choose f	rom the table below
	·						
		ple choice	Single cl	hoice possible	Single choice	oossible	Single choice possible
	possi						
	□ Bu	-	☐ Local		☐ Continuous		☐ Breakthrough
		abbing	☐ Gene	ralised	☐ Intermitten	t	☐ Incidental
		II Aching					☐ Spontaneous
		mbness					
	☐ Pri	ooting					
		asmodic					
	□ Jp						
_		.66					
	Н	Pain score				Please pr	ovide options from 0-10
	I	Duration				Days/We	eks/Months
	J	No of episodes of	ВТР	□0		Please pr	ovide options from 0-9
				□1			
				□ 2			
				□ 3			
				□ 4			
				□ 5 			
				□ 6			





		□ 7 □ 8	
		□ 9	
K	Aggravating Factors	☐ After meals ☐ On movement ☐ Not related ☐ On Swallowing ☐ Coughing ☐ Others	Multiple choice Possible
L	Pain Pathophysiology	☐ Somatic☐ Visceral☐ Neuropathic☐ Psychogenic	
Δ	Pain Syndrome	☐ Head and Neck Cancer Pain Syndrome ☐ Post Mastectomy Pain ☐ Visceral Pain Syndrome ☐ Pelvic Pain Syndrome ☐ Skeletal Metastasis ☐ STS Pain Syndrome ☐ Bracheal Plexopathy ☐ Lumbosacral Plexopathy ☐ Post Thoracotomy Pain ☐ Post RT Pain ☐ Post CT Pain ☐ Phantom Limb Pain ☐ CRPS	Multiple choice Possible
N	Pain diagnosis	☐ Due to cancer☐ Cancer Therapy☐ Unrelated	
0	Click to add/View Pain Image		
	Cida Effecta and Evilla		
6	Side Effects and Follow up		
	~F		
A	Side Effects	 □ None □ Vomiting □ Sedation/Drowsiness □ Constipation □ Hallucinations □ Pruritus □ Urinary Retention 	





В	Please mention the advice		Open text box		
С	Interim cancer treatment		Open text box		
D	Follow up after	☐ 1 day ☐ 2 days ☐ 1 week ☐ 10 days ☐ 20 days ☐ 1 month ☐ 3 months			
Е	Follow up date		Date to auto populate as per the option chosen		
	End				

5. PM- Part C: Pain Management Form- Nerve Block

Pain Management Form- Nerve Block						
Sno	Data elements	Clinician's Response	Remarks for Vendors			
1	General Details					
Α	Case No					
В	Name		Auto populate as per case no			
С	Age		Auto populate as per case no			
D	Sex		Auto populate as per case no			
Е	Diagnosis		Auto populate as per case no			
F	Phone Number		Auto populate as per case no			
G	Service	□ OPD				
		☐ Ward				
Н	Name of the Pain		Add the doctors as per the facility			
	Physician					
I	Surgery		Auto populate from EMR			





J	Chemotherapy		Auto populate from EMR
K	Radiotherapy		Auto populate from EMR
L	Pre- Existing Chronic disease	☐ COPD ☐ Epilepsy ☐ Asthma ☐ HT ☐ DM ☐ IHD ☐ Others ☐ None	Multiple Choice Possible
2	Procedure Details		
	·		
A	Name of the Block	□ Diagnostic Celiac plexus block □ Neurolytic Celiac Plexus block □ Glassopharyngeal Nerve block □ Mandibular Nerve Block □ Maxillary nerve block □ Stellate Ganglion block □ Sphenopalatine ganglion block □ Intercostal nerve blocks □ Superior hypogastric plexus block □ Ganglion impar block □ Hourolytic epidural block □ Subarachnoid Neurolytic Block □ Intrathecal morphine pump □ Epidural morphine □ Epidural steroids □ Lumbarsympathetic block □ Peripheral nerve blocks (Specify name of the nerve) □ Trigger Joint Injections □ Joint Injections □ Joint Injections □ Fascial plane blocks □ Other blocks (pls	





		specify)			
В	Approach/Procedure				
С	Date of Procedure				
D	Performed By				
Е	Assisted By				
F	Drug Used				
G	Concentration				
Н	Volume (ml)				
I	Image Guidance	☐ USG☐ Fluroscopy☐ CT scan☐ Landmark			
J	Contrast Used				
K	Volume (ml)				
3	Pre-Procedure				
A	Pulse/min				
В	BP mm/Hg				
С	Pain Score		Please provide options from 0-10		
4	Post Procedure				
Α	Pulse/min				
В	BP mm/Hg				
С	Pain Score		Please provide options from 0-10		
5	Immediate Complications				
Α	Immediate Complications		Open text box		
6	Status Change				
Α	Pre-Procedure Activity				
В	Post Procedure activity	☐ Worsened			
		☐ No change			
		☐ Improved			
End					





6. Appendices

Appendix 1- Glossary of terms

	Abbreviations	
NCG	National Cancer Grid	
EMR	Electronic Medical Record	
NER	NCG EMR Requirements	
LEAP	Leading EMR Adoption Program	
COPD	Chronic Obstructive Pulmonary Disease	
HT	Hypertension	
DM	Diabetes Mellitus	
IHD	Ischemic Heart Disease	
CAD	Coronary Artery Disease	
CVA	Cerebrovascular Accident	
ТВ	Tuberculosis	
RFT	Renal Function Test	
LFT	Liver Function Test	
BTP	Breakthrough Pain	
HS	At Bedtime	
CRPS	Complex Regional Pain Syndrome	
MDT	Multi-Disciplinary Tumor Board	
EOLC	End of life care	
LRTI	Lower Respiratory Tract Infection	
URTI	Upper Respiratory Tract Infection	

Appendix 2- NER Document

1. ncg-emr-requirements-ner.pdf (kcdo.in)